Information Provided By:
Fly News Breaks for August 6, 2019
PODD
Aug 6, 2019 | 09:02 EDT
BTIG analyst Sean Lavin raised his price target on Insulet to $140 and kept his Buy rating after its Q2 results and above-consensus Q3 guidance, saying the company is benefiting from "strong drivers" and the growing demand for diabetes technology, including both CGMs and insulin pumps. The analyst further cites Insulet's release of its new DASH platform and its "no-commitment" adoption model along with expanded payor coverage and its move toward the pharmacy channel combining to improve the ease of access to its technology for patients and payors.
News For PODD From the Last 2 Days
There are no results for your query PODD